Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash from Restructuring (2024 - 2025)

Historic Cash from Restructuring for Lyra Therapeutics (LYRA) over the last 2 years, with Q3 2025 value amounting to -$427000.0.

  • Lyra Therapeutics' Cash from Restructuring fell 12471.06% to -$427000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year change of. This contributed to the annual value of $4.3 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Lyra Therapeutics' Cash from Restructuring stood at -$427000.0, which was down 12471.06% from -$553000.0 recorded in Q2 2025.
  • In the past 5 years, Lyra Therapeutics' Cash from Restructuring registered a high of $1.7 million during Q3 2024, and its lowest value of -$553000.0 during Q2 2025.